Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

1 4

Cited 3 times in

Cited 0 times in

Authors: Lee, Sung Jong ; Yoo, Ji Geun ; Kim, Jin Hwi ; Park, Jeong-Yeol ; Lee, Jung-Yun ; Lee, Yoo-Young ; Suh, Dong Hoon

MeSH: Clinical Trials as Topic ; Female ; Humans ; Ovarian Neoplasms* / therapy ; Uterine Cervical Neoplasms* / pathology ; Uterine Cervical Neoplasms* / therapy ; Uterine Neoplasms* / therapy

Keywords: Gynecologic Neoplasms ; Immunotherapy ; Molecular Targeted Therapy ; Poly(ADP-Ribose) Polymerase Inhibitor ; Immunoconjugates

Abstract: This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.